Phase III trial of ipilimumab in metastatic melanoma demonstrates improvement in survival

被引：0
|
作者：
不详
机构：
来源：
FUTURE ONCOLOGY | 2010年 / 6卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1208 / 1208
页数：1
相关论文
共 50 条
  • [21] Phase 1 Dose Escalation Trial of Ipilimumab and Stereotactic Body Radiation Therapy in Metastatic Melanoma
    Sundahl, Nora
    De Wolf, Katrien
    Kruse, Vibeke
    Meireson, Annabel
    Reynders, Dries
    Goetghebeur, Els
    Van Gele, Mireille
    Speeckaert, Reinhart
    Hennart, Benjamin
    Brochez, Lieve
    Ost, Piet
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 100 (04): : 906 - 915
  • [22] Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
    Eggermont, A. M. M.
    Chiarion-Sileni, V.
    Grob, J. -J.
    Dummer, R.
    Wolchok, J. D.
    Schmidt, H.
    Hamid, O.
    Robert, C.
    Ascierto, P. A.
    Richards, J. M.
    Lebbe, C.
    Ferraresi, V.
    Smylie, M.
    Weber, J. S.
    Maio, M.
    Bastholt, L.
    Mortier, L.
    Thomas, L.
    Tahir, S.
    Hauschild, A.
    Hassel, J. C.
    Hodi, F. S.
    Taitt, C.
    de Pril, V.
    de Schaetzen, G.
    Suciu, S.
    Testori, A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19): : 1845 - 1855
  • [23] IPILIMUMAB IMPROVES SURVIVAL IN PREVIOUSLY TREATED, ADVANCED MELANOMA PATIENTS WITH POOR PROGNOSTIC FACTORS: SUBGROUP ANALYSES FROM A PHASE III TRIAL
    Lebbe, C.
    McDermott, D. F.
    Robert, C.
    Lorigan, P.
    Ottensmeier, C. H.
    Wolchok, J.
    Garbe, C.
    Messina, M.
    Hoos, A.
    Weber, J. S.
    ANNALS OF ONCOLOGY, 2010, 21 : 401 - 401
  • [24] Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial
    Di Giacomo, A. M.
    Sileni, V. Chiarion
    Del Vecchio, M.
    Ferrucci, P. F.
    Guida, M.
    Quaglino, P.
    Guidoboni, M.
    Marchetti, P.
    Cutaia, O.
    Amato, G.
    Gambale, E.
    Calabro, L.
    Valente, M.
    Danielli, R.
    Giannarelli, D.
    Mandala, M.
    Maio, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S734 - S734
  • [25] Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
    Weber, Jeffrey S.
    O'Day, Steven
    Urba, Walter
    Powderly, John
    Nichol, Geoff
    Yellin, Michael
    Snively, Jolie
    Hersh, Evan
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (36) : 5950 - 5956
  • [26] Ipilimumab approved for metastatic melanoma
    Traynor, Kate
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2011, 68 (09) : 768 - 768
  • [27] Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma
    Gibney, Geoffrey T.
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (17) : 1873 - U27
  • [28] Ipilimumab for metastatic uveal melanoma
    Gilbert, Judith A.
    LANCET ONCOLOGY, 2013, 14 (10): : E394 - E394
  • [29] Overall survival in patients with metastatic melanoma treated with concurrent ipilimumab and radiotherapy
    Koller, Kristian Michael
    Mackley, Heath B.
    Wagner, Henry
    Talamo, Giampaolo
    Schell, Todd
    Pameijer, Colette
    Neves, Rogerio Izar
    Anderson, Bryan
    Kokolus, Kathleen M.
    Mallon, Carol
    Drabick, Joseph J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] Metastatic Melanoma: Treatment and Survival in the US after the Introduction of Ipilimumab and Vemurafenib
    Enewold, Lindsey
    Sharon, Elad
    Harlan, Linda C.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (04) : 174 - 183
12345